论文部分内容阅读
本文报告通过对163 808例乳腺癌患者治愈生存模型进行对数计算来衡量肿瘤分期和组织学类型的预后价值。 对乳腺癌患者采取相应的治疗措施后,临床过程是由复杂的生物学机制决定的。治愈(CF)取决于是否仍存在病变,而与肿瘤相关的中位生存时间(MST)是由残留病变的进展速度决定的。治愈病例和严重恶化的比率通常采用非量化方法进行估计,难以用在临床试验中,因此必须采用量化方法,例如治愈可能的对数生存模型和具有内在量化性的平均生存时间相结合。 根据病理学结果和临床表现把病变划分为局限性、区域性和远处转移3种,局限性病变大约相当于TNM分期的Ⅰ期,区域性病变相当于Ⅱ期。随访时间1～227个月,每月随访一次。
This report reports the prognostic value of tumor staging and histological types by logarithmic calculations of 163 808 breast cancer patient survival survival models. After taking appropriate treatment measures for breast cancer patients, the clinical process is determined by complex biological mechanisms. The cure (CF) depends on whether the lesion is still present and the tumor-related median survival time (MST) is determined by the rate of progression of the residual lesion. The rate of cured cases and severe exacerbations is usually estimated using non-quantitative methods and is difficult to use in clinical trials. Therefore, quantitative methods such as the combination of a possible log survival model with an average survival time with intrinsic quantification must be used. According to pathological findings and clinical manifestations, lesions were divided into three types: localized, regional, and distant metastases. Localized lesions were equivalent to phase I of TNM staging, and regional lesions were equivalent to phase II. Follow-up time was 1 to 227 months and monthly follow-up.